PSMA PET-Positive Castration-Resistant Prostate Cancer Clinical Trials in Omaha, Nebraska

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)